Navigation Links
Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
Date:6/15/2011

ook for 2011

The agreement with Boehringer Ingelheim is expected to positively affect Zealand Pharma's revenues and other income by a total of DKK 150 (€20) million in 2011 but will not change the guidance on total operating expenses of DKK 170 (€23) million. Since Zealand Pharma's revenues stem from activity and success related milestone payments from partners, Zealand Pharma does not provide full year guidance on total revenues.

Zealand Pharma Conference call

Today, at 11:00am CET/ 10:00am BST/ 5:00am EST, Zealand Pharma will host a conference call, where David H. Solomon, President and Chief Executive Officer, will present this announcement. Mats Blom, Chief Financial Officer, and Hanne Leth Hillman, Vice President and Head of IR and Corporate Communications, will also participate in the call which will include a Q&A session.  The conference call will be conducted in English and the dial-in numbers are:

Denmark: +45-38-48-75-33

Europe:  +44(0)20-7138 0825

US:  +1-212-444-0481        

Confirmation Code: 4468737

About ZP2929

The biological rationale for developing ZP2929 is based on the pharmacology of the gut peptide hormone oxyntomodulin. Oxyntomodulin is released by the L-cells of the small intestine after meals, and is believed to exert its biological effects by activating both the glucagon receptor and the GLP-1 receptor. In humans, this hormone is believed to have multiple beneficial effects on diabetes and obesity, improving glucose tolerance and causing substantial weight loss.

ZP2929, which acts on both the glucagon and GLP-1 receptors, has shown in preclinical studies the ability to achieve glycemic control while causing significant and sustained weight loss. ZP2929 is being developed for once-daily subcutaneous administration to improve glycemic control and induce weight loss in patients with Type
'/>"/>

SOURCE Zealand Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
2. Prostate Cancer Patients Benefit from New Zealand Centers Adoption of Elekta VMAT Radiotherapy Technique
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
4. Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market
5. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
6. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
7. Saint-Gobains New C-Flex® ULTRA Pump Tubing for Biopharmaceutical Applications Outperforms the Competition
8. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
9. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
10. Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger
11. Cardinal Health Extends Radiopharmaceutical Manufacturing Network, Opening its First Cyclotron in Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... New technology in the form of a ... see and assess brain tissue more clearly while treating ... who released their findings today at the Society of ... Colorado Springs, CO. ... a specialty that facilitates stroke treatment by navigating a ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... CHICAGO, June 29, 2011 UBM Canon,s publishing group,s leading ... ), Medical Device and Diagnostic Industry ( ... Developments in Materials for Medical Applications " on May 24, ... virtual conference and trade show offered the opportunity to learn ...
... AUSTIN, Texas, June 29, 2011 Ascension Orthopedics, Inc., the ... the PyroTITAN™ Humeral Resurfacing Implant in Geelong, Australia by Richard ... "The patient was a 57-year-old, active male with ... by a fall from a mountain bike and not improved ...
Cached Medicine Technology:UBM Canon's Virtual Event Dedicated to Developments in Materials for Medical Applications 2UBM Canon's Virtual Event Dedicated to Developments in Materials for Medical Applications 3Ascension Orthopedics Implants PyroTITAN™ in Geelong, Australia 2
(Date:7/29/2014)... 2014 The Law Offices of Michael Cordova ... Hope, a non-profit organization providing grief camps for kids, teens, ... and suffering our clients experience from the death of a ... an organization like Stepping Stones of Hope, as they provide ... Stones of Hope also includes a monthly support group and ...
(Date:7/29/2014)... record the severity and regularity of their pain is ... , A new approach to the treatment of headaches, ... and is being led by Professor Paul Martin from ... He has developed an approach designed to enable people ... Learning to Cope with Triggers (LCT). , Using a ...
(Date:7/29/2014)... of cancer is to surgically remove the tumor. The ... surgeon may fail to extract the entire tumor, leading ... researchers at the University of Pennsylvania have established a ... in the patient, increasing the likelihood of a positive ... accumulates in cancerous tissues much more so than normal ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 A new ... during the 2014 Society for Cardiovascular Angiography and Interventions ... released this week. The videos review the benefits of ... services for the cardiac catheterization laboratory from the perspective ... the first video, Jane Kiah, MS, RN, Director of ...
(Date:7/29/2014)... boys with fragile X syndrome tend to decline ... of the inherited disorder to date has found. ... social and practical skills, including communication, socialization, and ... dressed. In this study, socialization emerged as a ... that it did not decline as much as ...
Breaking Medicine News(10 mins):Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 3Health News:Socialization relative strength in fragile X longitudinal study 2
... up with a remarkable discovery. Scientists there, have found ... have added benefits. Sildenafil and other drugs that help to ... chemical messenger seem to help in unveiling cancer cells. ... by that the immune system. , The ...
... Dr. Reddy's Laboratories will launch a first-of-its-kind pill to ... it was announced Thursday. // ,The company ... New Zealand, for trials of the groundbreaking 'polypill' that ... to treat heart ailments. , ,India records nearly ...
... multi vitamin supplements have a healthier diet and lifestyle ... ,Researchers led by Lindsay Reaves of the University of ... weight, diet and health behaviour of over 2,500 US ... , ,The study, which appeared in the December ...
... areas as part of a government plan to reach healthcare ... government has released initial funds to the tune of Rs. ... in rural areas. ,According to a health ministry ... Health Mission (NRHM) scheme for 2006-07. ,The ...
... is admissible to Orthopaedically Handicapped/Paraplegic persons, Completely Blind, ... (both afflictions together in the same person). Except ... all classes to other categories. Deaf & Dumb ... and First Class. Concession is granted in all ...
... The American Dental association announced on the 9th of November, ... preparation of infant formulation. // ,The dentists are concerned ... might be disastrous as instead of protecting teeth it might ... lead to weakened bones and even bone cancer boys. ...
Cached Medicine News:Health News:Impotency Drugs Help to Unmask Cancer Cells 2Health News:Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease 2
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
... bioprosthesis from Medtronic has more ... clinical experience. Worldwide clinical studies ... structural valve deterioration with Hancock® ... is substantially better than results ...
Attain Venogram Balloon Catheter....
... cardioverter defibrillators (ICDs) are designed to treat ... (SCD) due to arrhythmia. The size and ... is designed to facilitate ease of insertion ... 2 system incorporates Guidant's proprietary RHYTHM ID ...
Medicine Products: